Why Charles River Laboratories International, Inc. (CRL) stock moved
Charles River Laboratories International, Inc. (CRL) shares rose 3.9% to $351.87 as of November 4, 2026, a moderate gain from the prior close of $338.54. BestStocks flagged the session as a major change for CRL. The move is tied to price move down. Below, we break down what changed for CRL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CRL climbed 3.9% to $351.87
CRL rose 3.9% in its latest session, moving from $338.54 to $351.87.
What it means for Charles River Laboratories International, Inc. investors
For Charles River Laboratories International, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 3.9% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $308.36, implying -12.4% downside from $351.87. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (57/100). With earnings due imminently, the next report is the most likely near-term test of the move.
CRL price reaction
CRL last traded at $351.87, up $13.33 (+3.94%) from the previous close of $338.54. The session traded on 1.5× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $298.00 and $376.10, and it currently sits about 69% of the way up that band.
Bullish and bearish analyst opinions on Charles River Laboratories International, Inc. (CRL)
The consensus analyst price target on Charles River Laboratories International, Inc. (CRL) is $308.36, 12.4% below the recent $351.87. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CRL line up.
The bullish case
- The Street's most bullish target is $357.00 (+1.5%).
- 1 analyst upgrade in the past 90 days, most recently JP Morgan to Overweight (2026-08-06).
- Material positive event.
- Positive 3.9% session move.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $308.36 sits 12.4% below the recent $351.87, so the average target sees limited room to run.
- The most bearish analyst target is $219.00 (-37.8%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CRL
In-depth CRL event analyses
Frequently asked questions about CRL
Why did Charles River Laboratories International, Inc. (CRL) stock move?
CRL rose 3.9% to $351.87. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CRL stock rise?
CRL gained 3.94% ($13.33) versus the prior close of $338.54, last trading at $351.87 on 1.5× average volume.
When is Charles River Laboratories International, Inc.'s next earnings date?
CRL's next earnings report is scheduled for 2026-11-04 — about 0 days away.
What is the analyst price target for CRL?
The consensus analyst price target for CRL is $308.36, about 12.4% below the current $351.87. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 0 downgrades.
How BestStocks tracks CRL
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for CRL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.